SI-BONE (SIBN) CEO Laura Francis Sells $762K of Stock

CEO Laura Francis sold 38,006 shares of SI-BONE, Inc. (NasdaqGM: SIBN) on October 12, 2026, for a total of approximately $762,012 at a price of $20.05 per share. This transaction was planned in advance, indicating a strategy rather than a reaction to market conditions.

Inside Laura Francis's Trade

Laura Francis's sale of 38,006 shares represents a significant transaction, valued at about $762,012. The stock's recent trading price as of October 16, 2026, is around $19.25, which is below its target mean price of $25.44 set by analysts. This sale comes as the company continues to navigate its business in the medical device sector.

Other Institutional Activity in SI-BONE

First Light Asset Management, LLC increased its stake in SI-BONE by 2,774,639 shares, bringing its total to 8,127,985 shares worth about $159.96 million. Cadian Capital Management, LP also raised its position, adding 1,460,128 shares to reach 3,347,574 shares valued at approximately $65.88 million. Meanwhile, BlackRock Inc. added 247,872 shares for a total of 3,676,259 shares, valued at about $72.35 million.

SI-BONE, Inc. Stock Down 3.3%

As of October 16, 2026, SI-BONE's stock trades around $19.25, which is above its 52-week low of $11.48 but about 12.1% below its 52-week high of $21.89. The stock is trading above both its 50-day moving average of $18.94 and its 200-day moving average of $16.31, suggesting a recent positive trend despite the current price.

Recent Earnings

SI-BONE reported trailing twelve-month revenue of $213.6 million with a year-over-year revenue growth of 15.2%. However, the company has a negative net margin of -6.9% and a return on equity of -8.3%. The next earnings report is scheduled for November 9, 2026.

Insider Buying and Selling at SI-BONE, Inc.

On October 12, 2026, Laura Francis sold 38,006 shares at an average price of $20.05, totaling approximately $762,013. Earlier, on October 1, 2026, Director Jeffrey W. Dunn sold 20,000 shares at a price of $18.47, valued at $369,400. Other insiders, including Michael A. Pisetsky and Anshul Maheshwari, also sold shares in the days leading up to Francis's sale.

Analysts Set New Price Targets

On July 16, 2026, Truist Securities maintained a "Buy" rating with a price target of $21.00. UBS initiated coverage with a "Buy" rating and a price target of $24.00 on July 28, later raising it to $25.00 on August 4. The consensus rating remains a "strong buy" with a mean price target of $25.44 based on nine analyst opinions.

About SI-BONE

SI-BONE, Inc. specializes in developing medical devices for compromised bone conditions, focusing on biomechanical design and specific anatomical applications. The company offers patented titanium implants and related instruments, which are crucial for its operations in the healthcare sector.

Bottom Line

Investors should monitor SI-BONE's upcoming earnings report on November 9, 2026, as it may provide new insights into the company's performance and future direction. Laura Francis's recent sale of shares reflects ongoing adjustments among insiders at the company.